KRAS and cancer: The similar potency to inhibit the viability of KRAS G12D- and KRAS G12C-harboring cancer cell lines despite the higher affinity of binding by ITC assays to KRAS G12D over KRAS G12C could be due to KRB-456 inhibiting cell viability by not only binding, in the same cell line, to the mutant KRAS allele but also to the WT KRAS allele, which in ITC assays has a similar affinity to KRAS G12D.